Abstract 4340
Background
Pulmonary embolism (PE) is a common condition in patients with cancer, having a wide spectrum of clinical presentation (from acute life-threatening to truly asymptomatic incidental events). The aim of this study was to assess the prognostic relevance of the variable ‘setting’ (hospital-acquired vs. outpatient) at PE diagnosis.
Methods
Multicenter observational ongoing registry of consecutive patients with cancer-associated PE (2005-2018) including incidental and acute symptomatic events. The main outcome measured was the rate of overall and PE-specific 30-day mortality. Secondary outcomes were: rates of 30-day major bleeding (MB) and venous thromboembolism (VTE) recurrence.
Results
We included a total of 617 patients (61.6% male; median age 65 + 11.4 years; range 19-91 years) including N = 522 (85%) outpatients and N = 95 (15%) inpatients at PE diagnosis. The most frequent primary tumors were: lung 32%, colorectal 14%, urologic 13%, upper GI 12%, breast 9%, gynecologic 6% and other 9%). Most of the patients (79%) had metastatic cancer and nearly half (47%) were receiving chemotherapy.The PE was incidentally found in 54% of the cases. Overall 30-day mortality occurred in 95 patients (15% of the cohort), being greater in inpatients compared to outpatients (30% vs. 13%; p < 0.0001). Only 13 patients presented PE-related mortality (3% of the cohort), with no significant differences according to the setting at PE diagnosis (3.2% in inpatients vs. 1.7% in outpatients; p = 0.352). Similarly, there were no differences in 30-day MB (7.4% in inpatients vs. 4.4% in outpatients; p = 0.217) or VTE recurrence (4.2% in inpatients vs. 3.3% in outpatients; p = 0.637) according to the setting at PE diagnosis.
Conclusions
Hospital-acquired PE in cancer patients was associated with a greater overall 30-day mortality compared to outpatients at PE diagnosis. This finding may be relevant for the development of PE risk-assessment models in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Clínic de Barcelona.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract